A Phase Ib, Open-label Study of Safety and Pharmacokinetics of Volitinib in Combination With Docetaxel in Patients With Advanced Gastric Cancer
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2017
At a glance
- Drugs Docetaxel (Primary) ; Savolitinib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- Sponsors Hutchison MediPharma
- 29 Sep 2017 According to a Chi-Med media release, results were presented at the Chinese Society of Clinical Oncology (CSCO) 2017.
- 29 Sep 2017 Results presented in a Chi-Med media release.
- 01 Aug 2016 According to Chi-Med and AstraZeneca media release, first patient dosed in advanced gastric adenocarcinoma with second-line MET gene amplified patients during Q4 2014 and for Second-line MET overexpression patients during 4 2014.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History